Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 4
1(25.0%)
Phase 3
1(25.0%)
4Total
N/A(2)
Phase 4(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07495072Not ApplicableRecruiting

Early vs Delayed Intravesical Blad-Care During BCG Therapy

Role: collaborator

NCT06177808Not ApplicableUnknown

Assessment of Cutting-Balloon Angioplasty With Everolimus-Eluting Stent(EES) in the Treatment of Coronary Calcified Lesion(CCL) Guided by Intravascular Ultrasonography(IVUS)

Role: collaborator

NCT01554007Unknown

Clinical Course of Korean Crohn's Disease Cohort

Role: collaborator

NCT01365572Phase 4Unknown

New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )

Role: collaborator

NCT01037842Phase 3Completed

Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus

Role: collaborator

All 5 trials loaded